Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity

Journal of Bone and Mineral Research

Volumn 29, Issue 1, 2014, Pages 29-42

  Chang, Ming Kang ^a   Kramer, Ina ^a   Keller, Hansjoerg ^a   Gooi, Jonathan H ^a,d   Collett, Corinne ^b   Jenkins, David ^c   Ettenberg, Seth A ^c   Cong, Feng ^c   Halleux, Christine ^a   Kneissel, Michaela ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b HÔPITAL LARIBOISIÈRE   (France)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

genetic animal models; oppg; osteoporosis pseudoglioma; sclerosing bone disorders; SOST Sclerostin; WNT LRP5 6

Indexed keywords

DICKKOPF 1 PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; OSTEOCALCIN; SCLEROSTIN; WNT PROTEIN; WNT1 PROTEIN; WNT10A PROTEIN; WNT10B PROTEIN; WNT2 PROTEIN; WNT6 PROTEIN; WNT7A PROTEIN; WNT7B PROTEIN; WNT9A PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE DISEASE; BONE GROWTH; BONE MASS; BONE MINERAL; BONE STRUCTURE; CORTICAL BONE; FEMALE; FEMUR; GENOTYPE; IN VIVO STUDY; LUMBAR SPINE; MALE; MOUSE; NONHUMAN; NORRIE DISEASE; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OSTEOPOROSIS PSEUDOGLIOMA; PHENOTYPE; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; SCLEROSING BONE DISORDER; SOST DEFICIENCY; TRABECULAR BONE; UPREGULATION; WEIGHT GAIN; WNT SIGNALING PATHWAY;

GENETIC ANIMAL MODELS; OPPG; OSTEOPOROSIS-PSEUDOGLIOMA; SCLEROSING BONE DISORDERS; SOST/SCLEROSTIN; WNT/LRP5/6;

ANIMALS; BONE DENSITY; BONE DEVELOPMENT; GLYCOPROTEINS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-5; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-6; MICE; OSTEOGENESIS IMPERFECTA; TIBIA; WNT SIGNALING PATHWAY; X-RAY MICROTOMOGRAPHY;

EID: 84890100598     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2059     Document Type: Article

References (65)

1. Glass DA, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005; 8: 751-64.
2. Hill TP, Spater D, Taketo MM, Birchmeier W, Hartmann C., Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell. 2005; 8: 727-38.
3. Holmen SL, Zylstra CR, Mukherjee A, et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem. 2005; 280: 21162-8.
4. Kramer I, Halleux C, Keller H, et al. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol. 2010; 30: 3071-85.
5. Gong YQ, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001; 107: 513-23.
6. Holmen SL, Giambernardi TA, Zylstra CR, et al. Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res. 2004; 19: 2033-40.
7. Kato M, Patel MS, Levasseur R, et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol. 2002; 157: 303-14.
8. Kubota T, Michigami T, Sakaguchi N, et al. Lrp6 hypomorphic mutation affects bone mass through bone resorption in mice and impairs interaction with Mesd. J Bone Miner Res. 2008; 23: 1661-71.
9. Mani A, Radhakrishnan J, Wang H, et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science. 2007; 315: 1278-82.
10. Riddle RC, Diegel CR, Leslie JM, et al. Lrp5 and Lrp6 exert overlapping functions in osteoblasts during postnatal bone acquisition. PLOS One. 2013; 8: e63323.
11. Babij P, Zhao WG, Small C, et al. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res. 2003; 18: 960-74.
12. Boyden LM, Mao JH, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. New Engl J Med. 2002; 346: 1513-21.
13. Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002; 70: 11-9.
14. Pinzone JJ, Hall BM, Thudi NK, et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood. 2009; 113: 517-25.
15. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10: 537-43.
16. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 68: 577-89.
17. Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002; 39: 91-7.
18. Loots GG, Kneissel M, Keller H, et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005; 15: 928-35.
19. Staehling-Hampton K, Proll S, Paeper BW, et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002; 110: 144-52.
20. Kim SJ, Bieganski T, Sohn YB, et al. Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia. Hum Genet. 2011; 129: 497-502.
21. Li XD, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 23: 860-9.
22. Ai M, Holmen SL, Van Hul W, Williams BO, Warman ML., Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol. 2005; 25: 4946-55.
23. Balemans W, Piters E, Cleiren E, et al. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Calcif Tissue Int. 2008; 82: 445-53.
24. Ellies DL, Viviano B, McCarthy J, et al. Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5(G171V) to modulate Wnt activity. J Bone Miner Res. 2006; 21: 1738-49.
25. Semenov MV, He X., LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J Biol Chem. 2006; 281: 38276-84.
26. Li XF, Zhang YZ, Kang HS, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280: 19883-7.
27. Semenov M, Tamai K, Xi H., SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005; 280: 26770-5.
28. van Bezooijen RL, Svensson JP, Eefting D, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res. 2007; 22: 19-28.
29. Bourhis E, Wang WR, Tam C, et al. Wnt antagonists bind through a short peptide to the first beta-propeller domain of LRP5/6. Structure. 2011; 19: 1433-42.
30. Ettenberg SA, Charlat O, Daley MP, et al. Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc Natl Acad Sci U S A. 2010; 107: 15473-8.
31. Holdsworth G, Slocombe P, Doyle C, et al. Characterization of the interaction of sclerostin with the low density lipoprotein receptor-related protein (LRP) family of Wnt co-receptors. J Biol Chem. 2012; 287: 26464-77.
32. Leupin O, Piters E, Halleux C, et al. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem. 2011; 286: 19489-500.
33. Costa AG, Bilezikian JP., Sclerostin: therapeutic horizons based upon its actions. Curr Osteoporos Rep. 2012; 10: 64-72.
34. Kramer I, Loots GG, Studer A, Keller H, Kneissel M., Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res. 2010; 25: 178-89.
35. Kneissel M, Boyde A, Gasser JA., Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PT H(1-34). Bone. 2001; 28: 237-50.
36. Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013; 28: 2-17.
37. Keller H, Kneissel M., SOST is a target gene for PTH in bone. Bone. 2005; 37: 148-58.
38. Ahn VE, Chu MLH, Choi HJ, Tran D, Abo A, Weis WI., Structural basis of Wnt signaling inhibition by Dickkopf binding to LRP5/6. Dev Cell. 2011; 21: 862-73.
39. Cheng ZH, Biechele T, Wei ZY, et al. Crystal structures of the extracellular domain of LRP6 and its complex with DKK1. Nat Struct Mol Biol. 2011 Oct 9; 18 (11): 1204-10.
40. Collette NM, Genetos DC, Murugesh D, Harland RM, Loots GG., Genetic evidence that SOST inhibits WNT signaling in the limb. Dev Biol. 2010; 342: 169-79.
41. van Dinther M, Zhang J, Weidauer SE, et al. Anti-sclerostin antibody inhibits internalization of sclerostin and sclerostin-mediated antagonism of Wnt/LRP6 signaling. PLoS One. 2013; 8: e62295.
42. Kusu N, Laurikkala J, Imanishi M, et al. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem. 2003; 278: 24113-7.
43. Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003; 22: 6267-76.
44. Craig TA, Kumar R., Sclerostin-erbB-3 interactions: modulation of erbB-3 activity by sclerostin. Biochem Biophys Res Commun. 2010; 402: 421-4.
45. Devarajan-Ketha H, Craig TA, Madden BJ, Bergen HR, Kumar R., The sclerostin-bone protein interactome. Biochem Biophys Res Commun. 2012; 417: 830-5.
46. Yadav VK, Ryu JH, Suda N, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008; 135: 825-37.
47. Cui YJ, Niziolek PJ, MacDonald BT, et al. Lrp5 functions in bone to regulate bone mass. Nat Med. 2011 Jun; 17 (6): 684-91.
48. Joiner DM, Ke J, Zhong Z, Xu HE, Williams BO., LRP5 and LRP6 in development and disease. Trends Endocrinol Metab. 2013; 24: 31-9.
49. Laine CM, Joeng KS, Campeau PM, et al. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. New Engl J Med. 2013; 368: 1809-16.
50. Keupp K, Beleggia F, Kayserili H, et al. Mutations in WNT1 cause different forms of bone fragility. Am J Hum Genet. 2013; 92: 565-74.
51. Pyott SM, Tran TT, Leistritz DF, et al. WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. Am J Hum Genet. 2013; 92: 590-7.
52. Bennett CN, Longo KA, Wright WS, et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A. 2005; 102: 3324-9.
53. Robinson JA, Chatterjee-Kishore M, Yaworsky PJ, et al. Wnt/beta-catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem. 2006; 281: 31720-8.
54. Zhang YH, Wang Y, Li XF, et al. The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with mesd. Mol Cell Biol. 2004; 24: 4677-84.
55. Van Camp JK, Beckers S, Zegers D, et al. Genetic association study of WNT10B polymorphisms with BMD and adiposity parameters in Danish and Belgian males. Endocrine. 2013 Aug; 44 (1): 247-54.
56. Ayturk UM, Jacobsen CM, Christodoulou DC, et al. An RNA-seq protocol to identify mRNA expression changes in mouse diaphyseal bone: applications in mice with bone property altering Lrp5 mutations. J Bone Miner Res. Epub. 2013 Apr 2. DOI: 10.1002/jbmr.1946.
57. Sims AM, Shephard N, Carter K, et al. Genetic analyses in a sample of individuals with high or low BMD shows association with multiple Wnt pathway genes. J Bone Miner Res. 2008; 23: 499-506.
58. Korvala J, Jüppner H, Mäkitie O, et al. Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity. BMC Med Genet. 2012 Apr 10; 13: 26.
59. Baron R, Kneissel M., WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013; 19: 179-92.
60. Padhi D, Jang G, Stouch B, Fang LA, Posvar E., Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011; 26: 19-26.
61. Arantes HP, Barros ER, Kunii I, Bilezikian JP, Lazaretti-Castro M., Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma. J Bone Miner Res. 2011; 26: 2823-6.
62. Streeten EA, McBride D, Puffenberger E, et al. Osteoporosis-pseudoglioma syndrome: description of 9 new cases and beneficial response to bisphosphonates. Bone. 2008; 43: 584-90.
63. Gong Y, Bourhis E, Chiu C, et al. Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies. PLoS One. 2010; 5: e12682.
64. Gurney A, Axelrod F, Bond CJ, et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A. 2012; 109: 11717-22.
65. Yeh JR, Peterson RT., Novel Wnt antagonists target porcupine and Axin. Nat Chem Biol. 2009; 5: 74-5.